Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| BioRestorative Therapies, Inc.BRTX · Entity 8277 | VP, QA and Reg Compliance | February 13, 2024 | February 15, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
BioRestorative Therapies, Inc.
Report date February 13, 2024 · Filed February 15, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $1.45 · Expires 2034-02-13 | Direct | 219,298 |
Reported balance
After 2024-02-13 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-02-13 · Grant · Acquired 219,298 · Balance 219,298 F3: The option vests and becomes exercisable to the extent of 109,649 shares on February 13, 2024 with the remaining 109,649 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $5.08 · Expires 2031-11-04 | Direct | 8,277 |
Reported balance
Holding disclosure · report date 2024-02-13 · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · Balance 8,277 F1: The option is currently exercisable. |
| Stock OptionSEC Table II · derivative / convertible security · Conversion / exercise price $2.91 · Expires 2033-02-17 | Direct | 88,968 |
Reported balance
Holding disclosure · report date 2024-02-13 · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · Balance 88,968 F2: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. |
Filing footnotes · ownership attribution and instrument terms
F1: The option is currently exercisable.
F2: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested.
F3: The option vests and becomes exercisable to the extent of 109,649 shares on February 13, 2024 with the remaining 109,649 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 13, 2024 Filed Feb 15, 2024 16:19 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 219,298 | $0.00 Strike: $1.45 | $0.00 |
DisclosureSEC source: 0001021771-24-000050 · form4.xml · derivative · entry 3 Paccasassi Robert · CIK 0001751339 · VP, QA and Reg Compliance 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 219,298 Underlying: Common Stock · 219,298 shares Expires 2034-02-13 F3 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 109,649 shares on February 13, 2024 with the remaining 109,649 shares vesting in eight nearly-equal quarterly installments beginning on February 13, 2025 and continuing every three months thereafter until fully vested. Read SEC document |
| February 17, 2023 Filed Feb 17, 2023 21:39 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 88,968 | $0.00 Strike: $2.91 | $0.00 |
DisclosureSEC source: 0001567619-23-003365 · doc1.xml · derivative · entry 2 Paccasassi Robert · CIK 0001751339 · VP, QA and Reg Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 88,968 Underlying: Common Stock · 88,968 shares Expires 2033-02-17 F2 · derivative.exercise_date: The option vests and becomes exercisable to the extent of 44,484 shares on February 17, 2023 with the remaining 44,484 shares vesting in eight nearly-equal quarterly installments beginning on February 17, 2024 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 16:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 8,277 | $0.00 Strike: $5.08 | $0.00 |
DisclosureSEC source: 0001567619-22-019201 · doc1.xml · derivative · entry 2 Paccasassi Robert · CIK 0001751339 · VP, QA and Reg Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,277 Underlying: Common Stock · 8,277 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| November 03, 2022 Filed Nov 4, 2022 16:28 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 8,277 | $0.00 Strike: $13.50 | $0.00 |
DisclosureSEC source: 0001567619-22-019201 · doc1.xml · derivative · entry 1 Paccasassi Robert · CIK 0001751339 · VP, QA and Reg Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 8,277 shares Expires 2031-11-04 F2 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option with a reduced exercise price. F1 · derivative.exercise_date: The option vests and becomes exercisable in eight nearly-equal quarterly installments beginning on February 4, 2022 and continuing every three months thereafter until fully vested. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 8 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 50,000 | Not disclosed Strike: $1.23 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 7 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F4 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 40,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 6 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,000 Underlying: Common Stock · 40,000 shares Expires 2027-07-12 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 13,334 shares on July 12, 2018, and 13,333 shares on each of July 12, 2019 and July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 40,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 5 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 40,000 shares Expires 2027-07-12 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F3 · derivative.exercise_date: The option is exercisable to the extent of 13,334 shares on July 12, 2018, and 13,333 shares on each of July 12, 2019 and July 12, 2020. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 15,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 4 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2026-06-10 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 5,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 15,000 | Not disclosed Strike: $3.73 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 3 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires 2026-06-10 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F2 · derivative.exercise_date: The option is exercisable to the extent of 5,000 shares on each of June 10, 2017, June 10, 2018 and June 10, 2019. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 5,000 | Not disclosed Strike: $0.75 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 2 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,000 Underlying: Common Stock · 5,000 shares Expires 2025-08-13 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 1,667 shares on each of August 13, 2016 and August 13, 2017, and 1,666 shares on August 13, 2018. Read SEC document |
| March 25, 2019 Filed Mar 26, 2019 17:23 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | Disposition to issuerStock Option · Derivative | 5,000 | Not disclosed Strike: $4.70 | Not disclosed |
DisclosureSEC source: 0001567619-19-007665 · doc1.xml · derivative · entry 1 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 5,000 shares Expires 2025-08-13 F5 · price: The reported transactions involved an amendment of an outstanding stock option, resulting in the deemed cancellation of the "old" stock option and the grant of a "replacement" stock option at a reduced exercise price. F1 · derivative.exercise_date: The option is exercisable to the extent of 1,667 shares on each of August 13, 2016 and August 13, 2017, and 1,666 shares on August 13, 2018. Read SEC document |
| October 29, 2018 Filed Oct 31, 2018 16:02 UTC | BioRestorative Therapies, Inc. BRTX · Entity 8277 | GrantStock Option · Derivative | 50,000 | $0.00 Strike: $1.23 | $0.00 |
DisclosureSEC source: 0001567619-18-004864 · doc1.xml · derivative · entry 4 Paccasassi Robert · CIK 0001751339 · VP, Quality and Compliance 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,000 Underlying: Common Stock · 50,000 shares Expires 2028-10-29 F4 · derivative.exercise_date: The option is exercisable to the extent of 16,667 shares on each of October 29, 2019 and October 29, 2020, and 16,666 shares on October 29, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.